Literature DB >> 8181959

Production of interleukin 6 by granulomas of giant cell arteritis.

D Emilie1, E Liozon, M C Crevon, C Lavignac, A Portier, F Liozon, P Galanaud.   

Abstract

IL-6 serum levels are increased in patients suffering from GCA, and this cytokine may play a role in the systemic symptoms associated with this disease. We analyzed by in situ hybridization and immunohistochemistry whether IL-6 production originates from arterial granulomas in GCA. Seven arterial biopsy specimens taken from patients with histologically proved GCA were studied. IL-6 production was detected in all cases at both the mRNA and the protein levels. IL-6-producing cells were distributed in the intima, in the media, and in the adventitia. Positive cells were clearly enriched in the media, however, and particularly in contact with the internal elastic lamina. The morphology of the IL-6-producing cells showed that they belonged to several cell populations. In the media, most IL-6-producing cells were macrophages, whereas fibroblasts also produced IL-6 in the intima. Neither endothelial cells nor giant cells were found to express the IL-6 gene. Increased IL-6 serum concentrations returned to normal levels in most patients after administration of corticosteroids, indicating that inhibition of IL-6 production by GCA granuloma cells may be one of the mechanisms of action of corticosteroids in this condition. Production of IL-6 in abnormal arteries may thus participate to the systemic manifestations of GCA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8181959     DOI: 10.1016/0198-8859(94)90096-5

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  16 in total

1.  Giant cell arteritis and cardiovascular disease in older adults.

Authors:  J G Ray; M M Mamdani; W H Geerts
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

Review 2.  The Treatment of Giant Cell Arteritis.

Authors:  Imran Jivraj; Madhura Tamhankar
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598

3.  Acute stent thrombosis in a patient with giant cell arteritis.

Authors:  Jason Andrade; Abdullah Al Ali; Jacqueline Saw; Graham C Wong
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

Review 4.  Tocilizumab: a new therapy for large vessel vasculitis.

Authors:  Ibrahim A Al-Homood
Journal:  Clin Exp Med       Date:  2013-08-15       Impact factor: 3.984

5.  Design of the tocilizumab in giant cell arteritis trial.

Authors:  Sebastian H Unizony; Bhaskar Dasgupta; Elena Fisheleva; Lucy Rowell; Georg Schett; Robert Spiera; Jochen Zwerina; Olivier Harari; John H Stone
Journal:  Int J Rheumatol       Date:  2013-04-07

6.  Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab.

Authors:  Kazusato Hara; Masataka Umeda; Keiko Segawa; Midori Akagi; Yushiro Endo; Tomohiro Koga; Shin-Ya Kawashiri; Kunihiro Ichinose; Hideki Nakamura; Takahiro Maeda; Atsushi Kawakami
Journal:  Intern Med       Date:  2021-10-05       Impact factor: 1.282

7.  Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling.

Authors:  Kim Heang Ly; Alexis Régent; Elsa Molina; Sofiane Saada; Philippe Sindou; Claire Le-Jeunne; Antoine Brézin; Véronique Witko-Sarsat; François Labrousse; Pierre-Yves Robert; Philippe Bertin; Jean-Louis Bourges; Anne-Laure Fauchais; Elisabeth Vidal; Luc Mouthon; Marie-Odile Jauberteau
Journal:  Arthritis Res Ther       Date:  2014-11-24       Impact factor: 5.156

Review 8.  Cardiac allograft vasculopathy: current review and future research directions.

Authors:  Jordan S Pober; Sharon Chih; Jon Kobashigawa; Joren C Madsen; George Tellides
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

9.  Clinical use of biologics in vasculitis syndromes.

Authors:  Marino Paroli
Journal:  Biologics       Date:  2012-10-25

Review 10.  T cell-macrophage interactions and granuloma formation in vasculitis.

Authors:  Marc Hilhorst; Tsuyoshi Shirai; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2014-09-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.